Insulet Corp (PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Symbol
- PODD
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Devices
- Market cap
- $9.13B
- 52 week range
- 126.4 - 354.88
Valuation
- Share price
- $131.69 (close of 2026-10-02)
- P/E (TTM)
- 24.57x
- Price to book
- 6.42x
- Price to free cash flow
- 31.07x
- Enterprise value
- $9.54B
- Book value per share
- $20.52
Price performance
| Period | Change |
|---|---|
| 1 day | +0.69% |
| 5 days | -3.26% |
| 1 month | -11.10% |
| 3 months | -19.94% |
| 6 months | -35.54% |
| Year to date | -53.67% |
| 1 year | -57.82% |
| 3 years | -20.21% |
| 5 years | -53.85% |
| 10 years | +221.67% |
| All time | +725.13% |
Members of Congress who disclosed PODD trades
Markwayne Mullin · Tina Smith · Gilbert Ray Cisneros
Super investors holding PODD
Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- 16.31%
- Return on invested capital
- 21.82%
- Return on assets
- 7.75%
- Return on capital employed
- 18.87%
- Gross margin
- 71.63%
- Net margin
- 9.12%
- EBITDA margin
- 20.83%
- Revenue growth
- 30.73%
- Net income growth
- -40.93%
- Free cash flow growth
- 23.71%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 3.22%
- Current ratio
- 2.48x
- Net debt to EBITDA
- 0.63x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $2.71B
- Cost of revenue
- $768.20M
- Gross profit
- $1.94B
- EBITDA
- $564.20M
- Net income
- $247.10M
- Earnings per share
- $3.51
- Research and development
- $301.10M
- Shares outstanding
- 70.35M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $2.71B | $1.94B | $247.10M | $3.51 |
| 2024-12-31 | $2.07B | $1.45B | $418.30M | $5.97 |
| 2023-12-31 | $1.70B | $1.16B | $206.30M | $2.96 |
| 2022-12-31 | $1.06B | $805.60M | $4.60M | $0.07 |
| 2021-12-31 | $1.04B | $752.10M | $16.80M | $0.25 |
| 2020-12-31 | $904.40M | $582.30M | $6.80M | $0.11 |
| 2019-12-31 | $738.20M | $480.30M | $11.60M | $0.19 |
| 2018-12-31 | $563.80M | $370.20M | $3.30M | $0.06 |
| 2017-12-31 | $463.80M | $277.20M | -$26.80M | $-0.46 |
| 2016-12-31 | $366.99M | $211.09M | -$28.88M | $-0.48 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 71.63% | 9.12% | 16.31% | 21.82% |
| 2024-12-31 | 69.79% | 20.19% | 34.52% | 18.86% |
| 2023-12-31 | 68.35% | 12.16% | 28.16% | 14.66% |
| 2022-12-31 | 76.33% | 0.44% | 0.97% | 2.73% |
| 2021-12-31 | 72.28% | 1.61% | 3.02% | 11.80% |
| 2020-12-31 | 64.39% | 0.75% | 1.13% | 6.29% |
| 2019-12-31 | 65.06% | 1.57% | 15.28% | 6.13% |
| 2018-12-31 | 65.66% | 0.59% | 1.56% | 4.95% |
| 2017-12-31 | 59.77% | -5.78% | -16.91% | -2.60% |
| 2016-12-31 | 57.52% | -7.87% | -45.77% | -11.00% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $716.10M | - |
| 2024-12-31 | $953.40M | - |
| 2023-12-31 | $704.20M | - |
| 2022-12-31 | $689.80M | $1.37B |
| 2021-12-31 | $806.40M | $1.25B |
| 2020-12-31 | $907.20M | $1.04B |
| 2019-12-31 | $213.70M | $887.90M |
| 2018-12-31 | $288.94M | $592.00M |
| 2018-01-01 | $440.06M | $566.17M |
| 2017-12-31 | $440.06M | $566.17M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $377.70M | $62.70M |
| 2024-12-31 | $305.30M | $69.30M |
| 2023-12-31 | $70.10M | $48.40M |
| 2022-12-31 | -$3.90M | $40.90M |
| 2021-12-31 | -$180.00M | $34.40M |
| 2020-12-31 | -$45.00M | $35.90M |
| 2019-12-31 | -$65.30M | $28.70M |
| 2018-12-31 | -$121.50M | $37.50M |
| 2017-12-31 | -$32.50M | $31.90M |
| 2016-12-31 | -$6.20M | $23.62M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $1.59
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-05 | Jun/2026 | $1.44 |
| 2026-05-06 | Mar/2026 | $1.14 |
| 2026-02-18 | Dec/2025 | $1.48 |
| 2025-11-06 | Sep/2025 | $1.13 |
| 2025-08-07 | Jun/2025 | $0.93 |
| 2025-05-08 | Mar/2025 | $0.81 |
| 2025-02-20 | Dec/2024 | $1.05 |
| 2024-11-07 | Sep/2024 | $0.77 |
Filings and sources
- Company website
- insulet.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Globus Medical Inc (GMED) · Zimmer Biomet Holdings, Inc. (ZBH) · STERIS plc (STE) · GE HealthCare Technologies Inc. (GEHC) · McKesson Corp (MCK) · Cencora, Inc. (COR) · Cardinal Health Inc (CAH) · Henry Schein Inc (HSIC)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades